UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of ~~report~~Report (Date of earliest event reported): ~~March~~April 1015, 2023

PROMETHEUS BIOSCIENCES, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Delaware	001-40187	81-4282653
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3050 Science Park Road

San Diego, CA

92121

(Address of Principal Executive Offices)

(Zip Code)

San Diego, California 92121

(Address of principal executive offices) (Zip Code)

(858) 422-4300

(Registrant’s telephone number, ~~include~~including area code)

~~N/A~~Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	~~TradingSymbol~~Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	RXDX	The Nasdaq Global Select Market
Common Stock, $0.0001 par value per share	RXDX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 71.01. ~~Regulation~~Entry FDinto ~~Disclosure~~a Material Definitive Agreement.

~~Prometheus~~Agreement ~~Biosciences,~~and ~~Inc.~~Plan ~~(“Prometheus”) is aware that the Federal Deposit Insurance Corp. (“FDIC”) has taken control~~ of ~~Silicon~~Merger ~~Valley Bank (“SVB”) due to liquidity concerns. Prometheus does not hold any deposits at SVB or have any other direct investments at SVB.~~

~~The~~On ~~information~~April 15, ~~set~~2023, ~~forth~~Prometheus inBiosciences, ~~this Item 7~~Inc.01, isa ~~being~~Delaware ~~furnished~~corporation ~~pursuant~~(“Prometheus” toor ~~Item~~the ~~7.01~~“Company”), ~~and~~entered ~~shall~~into ~~not~~an beAgreement ~~deemed~~and ~~“filed”~~Plan ~~for~~of Merger (the ~~purposes~~“Merger ofAgreement”) ~~Section~~with Merck 18& ofCo., ~~the~~Inc., ~~Securities~~a ~~Exchange~~New ~~Act~~Jersey ofcorporation ~~1934~~(“Parent”), asand ~~amended,~~Splash orMerger ~~otherwise~~Sub, ~~subject~~Inc., toa ~~the~~Delaware ~~liabilities~~corporation ~~of that section~~ and itwholly ~~shall~~owned ~~not~~subsidiary beof ~~deemed~~Parent ~~incorporated~~(“Merger bySub”), ~~reference~~pursuant into ~~any~~which, ~~filing~~and ~~under~~on the ~~Securities~~terms ~~Act~~and ofsubject ~~1933,~~to asthe ~~amended~~conditions thereof, orMerger ~~under~~Sub ~~the~~will ~~Exchange~~merge ~~Act,~~with ~~whether~~and ~~made~~into ~~before~~the orCompany, ~~after~~with the ~~date~~Company ~~hereof,~~surviving ~~except~~ as ~~expressly~~a ~~provided~~wholly byowned ~~specific~~subsidiary ~~reference~~of inParent ~~such~~(the ~~a filing~~“Merger”).

Subject to the terms and conditions of the Merger Agreement, each share of Company common stock, par value $0.0001 per share (each a “Company Share”) that is issued and outstanding immediately prior to the effective time of the Merger (the “Effective Time”), other than any Company Shares (i) owned immediately prior to the Effective Time by Parent, Merger Sub or the Company or by any direct or indirect wholly owned subsidiary of Parent, Merger Sub or the Company or (ii) owned by Company stockholders who are entitled to demand and have properly and validly demanded their appraisal rights under Delaware law, will be canceled and extinguished and automatically converted into the right to receive $200.00 per share in cash (the “Merger Consideration”), without interest and subject to any applicable withholding taxes.

In addition, effective as of immediately prior to the Effective Time, (i) each outstanding Company stock option, whether vested or unvested, will be automatically canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (A) the number of Company Shares underlying such option immediately prior to the Effective Time multiplied by (B) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, (ii) each outstanding Company restricted stock unit (“RSU”) will be automatically canceled and converted into the right to receive an amount in cash equal to the product of (A) the number of Company Shares underlying such RSU immediately prior to the Effective Time multiplied by (B) the Merger Consideration, without interest and subject to any applicable withholding taxes and (iii) each outstanding share of restricted stock of the Company will automatically become fully vested and converted into the right to receive the Merger Consideration.

The Merger Agreement contains customary representations, warranties and covenants, including covenants obligating the Company to use commercially reasonable efforts to conduct its operations according to its ordinary course of business, to cooperate in seeking regulatory approvals and not to engage in certain specified activities without Parent’s prior consent. In addition, subject to certain exceptions, the Company has agreed not to solicit, initiate, knowingly encourage, or knowingly facilitate, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to an Acquisition Proposal (as defined in the Merger Agreement), or take certain other restricted actions in connection therewith. Notwithstanding the foregoing, if the Company receives a written, bona fide Acquisition Proposal that did not result from a material breach of the non-solicitation provisions of the Merger Agreement that the Company’s Board of Directors (the “Board”) determines in good faith, after consultation with its financial advisor(s) and outside legal counsel, constitutes or is reasonably likely to lead to a Superior Proposal (as defined in the Merger Agreement), the Company may take certain actions to participate in discussions and negotiations and furnish information with respect to such Acquisition Proposal, after providing written notice to Parent of such determination.

The Company will prepare and file a proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) and, subject to certain exceptions, the Board will recommend that the Merger Agreement be adopted by the Company’s stockholders at a special meeting of the Company’s stockholders (the “Company Board Recommendation”). However, subject to the satisfaction of certain terms and conditions, the

Company and the Board, as applicable, are permitted to take certain actions which may, as more fully described in the Merger Agreement, include changing the Company Board Recommendation and entering into a definitive agreement with respect to a Superior Proposal if, among other things, the Board has concluded in good faith after consultation with its outside legal counsel that the failure to take such action would be reasonably likely to be inconsistent with the Board’s fiduciary duties under applicable law.

The Merger Agreement also contains certain customary termination rights in favor of each of the Company and Parent, including the Company’s right, subject to certain limitations, to terminate the Merger Agreement in certain circumstances to accept a Superior Proposal and Parent’s right to terminate the Merger Agreement if the Board changes its Company Board Recommendation. In addition, either Parent or the Company may terminate the Merger Agreement if the Merger has not been successfully completed by April 15, 2024 (the “Termination Date”). In connection with a termination of the Merger Agreement under specified circumstances, including due to a change in the Company Board Recommendation, the entry by the Company into a definitive agreement with respect to a Superior Proposal, or certain other triggering events, the Company may be required to pay Parent a termination fee of $325,364,166. In addition, in connection with a termination of the Merger Agreement under specified circumstances, including due to a failure to effect the Merger prior to the Termination Date because of an inability to obtain the necessary competition approvals or due to the entry of a final, non-appealable antitrust law or order permanently restraining, enjoining, preventing, or prohibiting the Merger, Parent may be required to pay the Company a termination fee of $650,728,333.

The Board has unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Merger, are advisable, fair to and in the best interests of the Company and its stockholders, and declared it advisable for the Company to enter into the Merger Agreement, (ii) approved and declared advisable the execution and delivery by the Company of the Merger Agreement, the performance by the Company of its covenants and agreements contained in the Merger Agreement and the consummation of the Merger and the other transactions contemplated by the Merger Agreement upon the terms and subject to the conditions contained therein, (iii) directed that the adoption of the Merger Agreement be submitted to a vote at a meeting of the holders of Company Shares and (iv) resolved, subject to the terms and conditions set forth in the Merger Agreement, to recommend that the holders of Company Shares adopt the Merger Agreement at such meeting of the Company’s stockholders.

The foregoing description of the Merger Agreement and the transactions contemplated thereunder is not complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is hereby filed as Exhibit 2.1 to this Current Report on Form 8-K (this “Current Report”) and incorporated herein by reference. The Merger Agreement and the foregoing description thereof have been included to provide investors and stockholders with information regarding the terms of the Merger Agreement. They are not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Merger Agreement were made only as of specified dates for the purposes of such agreement, were solely for the benefit of the parties to such agreement and may be subject to qualifications and limitations agreed upon by such parties. In particular, in reviewing the representations, warranties and covenants contained in the Merger Agreement and discussed in the foregoing description, it is important to bear in mind that such representations, warranties and covenants were negotiated with the principal purpose of allocating risk between the parties, rather than establishing matters as facts. Such representations, warranties and covenants may also be subject to a contractual standard of materiality different from those generally applicable to stockholders and reports and documents filed with the SEC, and are also qualified in important part by a confidential disclosure schedule delivered by the Company to Parent in connection with the Merger Agreement. Investors and stockholders are not third-party beneficiaries under the Merger Agreement. Accordingly, investors and stockholders should not rely on such representations, warranties and covenants as characterizations of the actual state of facts or circumstances described therein. Information concerning the subject matter of such representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the parties’ public disclosures.

Item 7.01

Regulation FD Disclosure.

On April 16, 2023, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is hereby furnished as Exhibit 99.1 to this Current Report.

The information contained in this Item 7.01 and in Exhibit 99.1 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

2.1*		Agreement and Plan of Merger, dated as of April 15, 2023, by and among Prometheus Biosciences, Inc., Merck & Co., Inc., and Splash Merger Sub, Inc.

99.1		Press Release, dated April 16, 2023.

104		Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.

Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits or schedules so furnished.

Forward-Looking Statements

~~Prometheus~~This ~~cautions~~Current ~~you~~Report ~~that~~contains forward-looking statements ~~included~~within the meaning of federal securities laws. Forward-looking statements in this ~~report~~Current ~~that~~Report include, but are not alimited ~~description~~to, ofstatements ~~historical~~regarding ~~facts~~the ~~are~~consummation ~~forward-looking~~of ~~statements~~the transaction described above. These forward-looking statements ~~include~~involve ~~statements~~a ~~regarding~~number ~~any~~of ~~liquidity~~risks ~~concern.~~and ~~The~~uncertainties ~~inclusion~~that ofcould cause actual results to differ materially from those indicated in such forward-looking statements, ~~should~~including but not belimited ~~regarded~~to asthe aability ~~representation~~of bythe ~~Prometheus~~parties to consummate the proposed Merger and the possibility that ~~any~~various ofclosing ~~these~~conditions ~~results~~for ~~will~~the proposed Merger may not be ~~achieved.~~satisfied ~~Actual~~or ~~results~~waived, ~~may~~and ~~differ~~the ability to realize the benefits expected from ~~those~~the ~~set~~proposed ~~forth~~Merger. The forward-looking statements in this ~~report~~Current ~~due~~Report toare ~~the~~based ~~risks~~on ~~and~~information ~~uncertainties~~available ~~associated~~to ~~with~~Prometheus ~~liquidity~~as ~~concerns~~of ~~that~~the ~~may~~date ~~affect~~hereof, ~~other~~and ~~banking~~Prometheus ~~institutions,~~disclaims asany ~~well~~obligation asto ~~risks~~update ~~and~~any ~~uncertainties~~forward-looking ~~inherent~~statements to reflect any change in ~~Prometheus’~~its ~~business,~~expectations ~~including~~or ~~those~~any ~~described~~change in ~~Prometheus’~~events, ~~other~~conditions, ~~filings~~or ~~with~~circumstances ~~the~~on ~~Securities~~which ~~Exchange~~any ~~Commission.~~such ~~You~~statement ~~are~~is ~~cautioned~~based, ~~not~~except toas ~~place~~required ~~undue~~by ~~reliance~~law. onFor ~~these~~additional information regarding forward-looking statements, ~~which~~please ~~speak~~refer ~~only~~to asdiscussions ofunder the ~~date~~captions ~~hereof,~~“Risk Factors” and ~~Prometheus~~“Management’s ~~undertakes~~Discussion noand ~~obligation~~Analysis toof ~~revise~~Financial orCondition ~~update~~and ~~this~~Results ~~report~~of toOperation” ~~reflect~~and ~~events~~elsewhere orin ~~circumstances~~our ~~after~~most ~~the~~recent ~~date~~Annual ~~hereof.~~Report ~~All~~on ~~forward~~Form 10-~~looking~~K ~~statements~~and ~~are qualified~~ in ~~their~~our ~~entirety~~other byreports ~~this~~filed ~~cautionary~~with ~~statement~~the SEC. ~~This~~Prometheus’ ~~caution~~SEC isfilings ~~made~~are ~~under~~available on the ~~safe~~Investor ~~harbor~~Relations ~~provisions~~section of ~~Section 21E~~our ofwebsite ~~the~~at ~~Private~~https://ir.prometheusbiosciences.com/investor-relations ~~Securities~~and ~~Litigation~~on ~~Reform~~the ~~Act~~SEC’s ofwebsite ~~1995~~at www.sec.gov.

~~SIGNATURES~~The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: (i) the proposed Merger may not be completed in a timely manner or at all, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Prometheus or the expected benefits of the proposed Merger or that the approval of Prometheus’ stockholders is not obtained; (ii) the failure to realize the anticipated benefits of the proposed Merger; (iii) the possibility that competing offers or acquisition proposals for Prometheus will be made; (iv) the possibility that any or all of the various conditions to the consummation of the proposed Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed Merger, including in circumstances which would require Prometheus to pay a termination fee or other expenses; and (vi) the effect of the announcement or pendency of the proposed Merger on Prometheus’ ability to retain and hire key personnel, or its operating results and business generally.

Additional Information

This Current Report may be deemed solicitation material in respect of the proposed acquisition of the Company. A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed Merger between the Company and Parent. The Company expects to file with the SEC a proxy statement and other relevant documents in connection with the proposed Merger. Investors of the Company are urged to read the definitive proxy statement and other relevant materials carefully and in their entirety when they become available because they will contain important information about the Company and the proposed Merger. Investors may obtain a free copy of these materials (when they are available) and other documents filed by the Company with the SEC at the SEC’s website at www.sec.gov and at the Company’s website at https://www.prometheusbiosciences.com.

Participants in the Solicitation

The Company and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed Merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of the Company’s stockholders in connection with the proposed Merger will be set forth in the Company’s definitive proxy statement for its special stockholder meeting. Additional information regarding these individuals and any direct or indirect interests they may have in the proposed Merger will be set forth in the definitive proxy statement when and if it is filed with the SEC in connection with the proposed Merger.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROMETHEUS BIOSCIENCES, INC.
Dated: April 17, 2023	PROMETHEUS BIOSCIENCES, INC.
Date: March 10, 2023	By:	/s/ Timothy K. Andrews
	By:	/s/ Timothy K. Andrews
		Timothy K. Andrews
	Name:	Timothy K. Andrews
		General Counsel and Secretary
	Title:	General Counsel and Secretary

Filing Compare · Prometheus Biosciences, Inc.